Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤Total net product revenue $259.7 million, up 52% year-over-year
- ➤AUVELITY net product sales $207.6 million, up 53% year-over-year
- ➤SYMBRAVO net product sales $3.9 million, up 88% year-over-year
- ➤Net loss narrowed to $12.9 million, or $(0.25) per share
- ➤SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated
Expert Statements
Herriot Tabuteau, Chief Executive Officer of Axsome Therapeutics
“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation”
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth
AUVELITY(®) 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth
Get started
Create a free account to read the full story.